NAACOS and Innovaccer Latest Report Shows 64% of Healthcare Leaders Expect Revenue Gains from Value-Based Care in 2025
SAN FRANCISCO--(BUSINESS WIRE)-- Innovaccer Inc., a leading healthcare AI company, in collaboration with the National Association of ACOs (NAACOS), today announced the release of their joint report, ' The State and Science of Value-Based Care 2025.' Based on a nationwide survey of 168 healthcare leaders across 142 organizations, the study uncovers the progress, pain points, and investment signals driving value-based care (VBC) strategies forward.
As the healthcare industry moves toward outcomes-based models, 64% of surveyed organizations expect a positive revenue shift from value-based care in 2025, marking a sharp increase in confidence despite ongoing structural and operational challenges.
'As the shift to value-based care accelerates, the research highlights a critical truth: successful transformation demands more than just intent, it requires deep investments in data, technology, and partnerships,' said Abhinav Shashank, cofounder and CEO of Innovaccer. 'This joint report with NAACOS provides clarity and direction for healthcare leaders navigating the complexities of modern reimbursement models.'
Key findings in the report include:
64% of healthcare organizations expect higher VBC-driven revenue in 2025 compared to 2024.
87% of respondents cite financial risk as the top barrier to adoption, followed by provider readiness (80%), lack of interoperability (75%), and high technology cost (67%).
74% say greater financial support and incentives would significantly accelerate adoption.
70% express optimism about AI's role in enabling predictive analytics and scaling VBC strategies.
'At the foundation of accountable care and population health management lies the strategic use of integrated data that drives insights and action,' said Emily D. Brower, President and CEO of NAACOS. 'This comprehensive approach enables a deeper understanding of community, population, and individual patient needs. This report highlights how technology, collaboration, and infrastructure can support providers in accountable care to drive innovation in care delivery.'
The report also highlights how high-performing organizations are laying the foundation for long-term VBC success through unified data platforms, advanced analytics, and integrated care delivery solutions.
Download the full report here.
About Innovaccer
Innovaccer activates the flow of healthcare data, empowering providers, payers, and government organizations to deliver intelligent and connected experiences that advance health outcomes. The Healthcare Intelligence Cloud equips every stakeholder in the patient journey to turn fragmented data into proactive, coordinated actions that elevate the quality of care and drive operational performance. Leading healthcare organizations like CommonSpirit Health, Atlantic Health, and Banner Health trust Innovaccer to integrate a system of intelligence into their existing infrastructure— extending the human touch in healthcare. For more information, visit innovaccer.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Barth Syndrome Foundation Responds to FDA's Proposed 'Path Forward' for Elamipretide
Families face more delay despite dire need, strong data and years and years of effort BOSTON, May 29, 2025--(BUSINESS WIRE)--The Barth Syndrome Foundation (BSF) today responded to new developments from the U.S. Food and Drug Administration (FDA) regarding elamipretide, a potential treatment for the ultra-rare and life-threatening condition. Despite an already lengthy review and a 10-6 favorable FDA Cardiovascular and Renal Drugs Advisory Committee vote last October, the FDA now has indicated to Stealth BioTherapeutics that the agency will not approve the current application for this drug. However, for the first time, the agency issued a written recommendation outlining a potential path to accelerated approval based on previously submitted data showing more than 45 percent improvement in muscle strength and its correlation with increased physical function. "It's unconscionable that it now will take even longer for the FDA to rule on this drug for our very small population with no other specific therapies," said Emily Milligan, executive director, Barth Syndrome Foundation. "This administration has sent strong signals it's serious about defining a process that works for rare disease families. Now is the time to deliver. We need FDA leadership to take strong, decisive action and put an end to the hemming and hawing. This literally translates into life, death and better lives for our children." Barth syndrome is an ultra-rare, life-threatening genetic disorder primarily affecting males. There are no FDA-approved treatments and no other therapies in late-stage clinical development. Clinical studies show elamipretide can improve mitochondrial function and boost muscle strength by 45 percent and heart function by 40 percent in patients with Barth syndrome. Most patients from the original trial continue to take and benefit from this therapy more than eight years after initiating treatment. Many more individuals, mostly infants, in acute cardiac distress have received elamipretide through emergency access requests approved by the FDA. Despite the extensive safety record and strong vote of the advisory committee, the FDA has not granted approval. Nearly 20 percent of U.S. patients with Barth syndrome are currently receiving elamipretide through an expanded access program. The FDA's current proposed path, unfortunately, excludes the sickest babies, who make up a majority of those currently receiving the drug through emergency access. Over half of deaths in Barth syndrome occur in the first few years of life. Yet the FDA has declined to include these patients in the potential approval path, citing a lack of feasibility for pre-approval studies. "No safety concerns have been raised, and the agency acknowledged the difficulty of conducting traditional trials in a disease this rare," Milligan said. "Still, families are left in limbo, waiting on a treatment that medical experts, patient experiences and common sense overwhelmingly support." More than 50 clinicians and nearly 20,000 people from across the globe have signed letters and petitions over the last few years urging the FDA to approve elamipretide without further delay. Their views echo the lived experience of families and patients who have endured years of uncertainty. "With no approved therapies and limited access to treatment, every day of inaction carries a devastating cost," Milligan said. "The FDA made a promise to our community—to conduct a fair, thorough and equitable review of elamipretide through the advisory committee process. That promise remains unfulfilled." Stories Behind the Science Families from across the country continue to fight for access to a treatment that could mean survival. Their stories offer a powerful reminder of what is at stake: In Mississippi, a mother describes her desperate effort to keep her son alive with no other options: "Mississippi's Heartbeat" In California, one physician's 3 a.m. call from the ICU leads to a life-saving intervention: "In the ICU at 3 a.m." In Ohio, a family spanning two generations shares what this drug means to them: "Two Generations, One Drug" In Texas, a newborn's life is saved just in time by emergency access: "A Life Saved in the Nick of Time" In Georgia, one family measures survival in milligrams and urgency: "A Life Measured in Milligrams" In New York, a 13-year fight shows what resilience in rare disease looks like: "Too Rare to Care" And in Oklahoma, one young man explains why elamipretide is the drug that gave him his life back: "Walker Burger's Fight" Each of these families speaks with one voice: the time to approve this treatment is now. About Barth Syndrome Foundation (BSF) Barth Syndrome Foundation and our international affiliates comprise the only global network of families, health care providers, and researchers solely driven by the mission to save lives through education, advances in treatments, and finding a cure for Barth syndrome. Considered a role model in rare disease advocacy, BSF has funded $7 million and catalyzed more than $41.4 million in funding from other sources to advance global scientific discoveries. BSF also provides a lifeline to families around the world through individualized support, educational conferences, a patient registry, and collaborations with expert providers to define standards of care, treatment, and rapid diagnosis. View source version on Contacts BSF Media Contact: Matt Burnsmatt@ 518-423-5907
Business Wire
an hour ago
- Business Wire
Barth Syndrome Foundation Responds to FDA's Proposed 'Path Forward' for Elamipretide
BOSTON--(BUSINESS WIRE)--The Barth Syndrome Foundation (BSF) today responded to new developments from the U.S. Food and Drug Administration (FDA) regarding elamipretide, a potential treatment for the ultra-rare and life-threatening condition. "We need FDA leadership to take strong, decisive action and put an end to the hemming and hawing. This literally translates into life, death and better lives for our children." Despite an already lengthy review and a 10-6 favorable FDA Cardiovascular and Renal Drugs Advisory Committee vote last October, the FDA now has indicated to Stealth BioTherapeutics that the agency will not approve the current application for this drug. However, for the first time, the agency issued a written recommendation outlining a potential path to accelerated approval based on previously submitted data showing more than 45 percent improvement in muscle strength and its correlation with increased physical function. 'It's unconscionable that it now will take even longer for the FDA to rule on this drug for our very small population with no other specific therapies,' said Emily Milligan, executive director, Barth Syndrome Foundation. 'This administration has sent strong signals it's serious about defining a process that works for rare disease families. Now is the time to deliver. We need FDA leadership to take strong, decisive action and put an end to the hemming and hawing. This literally translates into life, death and better lives for our children.' Barth syndrome is an ultra-rare, life-threatening genetic disorder primarily affecting males. There are no FDA-approved treatments and no other therapies in late-stage clinical development. Clinical studies show elamipretide can improve mitochondrial function and boost muscle strength by 45 percent and heart function by 40 percent in patients with Barth syndrome. Most patients from the original trial continue to take and benefit from this therapy more than eight years after initiating treatment. Many more individuals, mostly infants, in acute cardiac distress have received elamipretide through emergency access requests approved by the FDA. Despite the extensive safety record and strong vote of the advisory committee, the FDA has not granted approval. Nearly 20 percent of U.S. patients with Barth syndrome are currently receiving elamipretide through an expanded access program. The FDA's current proposed path, unfortunately, excludes the sickest babies, who make up a majority of those currently receiving the drug through emergency access. Over half of deaths in Barth syndrome occur in the first few years of life. Yet the FDA has declined to include these patients in the potential approval path, citing a lack of feasibility for pre-approval studies. 'No safety concerns have been raised, and the agency acknowledged the difficulty of conducting traditional trials in a disease this rare,' Milligan said. 'Still, families are left in limbo, waiting on a treatment that medical experts, patient experiences and common sense overwhelmingly support.' More than 50 clinicians and nearly 20,000 people from across the globe have signed letters and petitions over the last few years urging the FDA to approve elamipretide without further delay. Their views echo the lived experience of families and patients who have endured years of uncertainty. 'With no approved therapies and limited access to treatment, every day of inaction carries a devastating cost,' Milligan said. 'The FDA made a promise to our community—to conduct a fair, thorough and equitable review of elamipretide through the advisory committee process. That promise remains unfulfilled.' Stories Behind the Science Families from across the country continue to fight for access to a treatment that could mean survival. Their stories offer a powerful reminder of what is at stake: Each of these families speaks with one voice: the time to approve this treatment is now. About Barth Syndrome Foundation (BSF) Barth Syndrome Foundation and our international affiliates comprise the only global network of families, health care providers, and researchers solely driven by the mission to save lives through education, advances in treatments, and finding a cure for Barth syndrome. Considered a role model in rare disease advocacy, BSF has funded $7 million and catalyzed more than $41.4 million in funding from other sources to advance global scientific discoveries. BSF also provides a lifeline to families around the world through individualized support, educational conferences, a patient registry, and collaborations with expert providers to define standards of care, treatment, and rapid diagnosis.
Business Wire
6 hours ago
- Business Wire
AHF Poland Joins Calls for Period Equity on Menstrual Health Day
LUBLIN, Poland--(BUSINESS WIRE)--Join AIDS Healthcare Foundation (AHF) Poland for a Menstrual Health Day commemorative event at the Center for Culture on Saturday, May 31, 2025, at 16.00 to address the stigma, cultural taboos, and lack of menstrual hygiene access that undermine dignity and increase HIV risk among women and girls/people who menstruate. Menstrual Health Day is observed annually on May 28. Globally, women and girls, particularly in regions like sub-Saharan Africa, face a disproportionate HIV burden. The lack of access to sanitary pads forces many to miss school, increasing the likelihood of dropping out. This often leads to increased transactional or transgenerational sex, limiting their ability to negotiate safer sex and raising the risk of acquiring HIV. AHF's Menstrual Health Day commemorations worldwide are part of broader strategic prevention efforts that highlight the link between menstrual health and HIV, promote the availability and accessibility of menstrual products, and integrate sexual and reproductive health information and services—ensuring women and girls/ people who menstruate have access to sanitary pads, HIV testing, condoms, and essential care. Therefore, on the occasion of this year's Menstrual Health Day, AHF Poland will: Donate menstrual hygiene products to women refugees from the Center for Foreigners in Łuków. Provide equipment for the "Pink Boxes" at the Lublin University of Technology, the Youth Spaces network in Lublin, and integration spaces—Spilno Lublin and Baobab. The donation of menstrual products to Lublin University of Technology will be accompanied by a lecture titled "Menstrual Health Taken Seriously." Organize a special workshop with a urogynecological physiotherapy specialist and doctor, who will debunk common myths about menstruation ("That's just how you are,""PMS is a natural part of life") and demonstrate how movement techniques and massage can help relieve period discomfort. The workshop will also feature free pads and tampons, information on sexual health, quick HIV testing, live music, drinks, and snacks. The event will be international and conducted in both Polish and English. WHAT: PERIOD POWER! Menstrual Health Workshop Featuring: Natalia Brzozowska-Struska, urogynecological physiotherapist Michalina Pytka, doctor and menstrual health expert at Kulczyk Foundation Live music performance by Ev, an artist, poet, actress, and screenwriter from Zimbabwe During the workshop, menstrual pads and tampons will be distributed, and free HIV tests and informational materials on sexual and reproductive health will be available. WHEN: Saturday, May 31, 2025 TIME: 16:00 – 20:00 WHERE: Center for Culture (Centrum Kultury), Peowiaków 12 WHO: Natalia Brzozowska-Struska – urogynecological physiotherapist Michalina Pytka – doctor and menstrual health expert at the Kulczyk Foundation Ev – artist from Zimbabwe Girls, young women, and adult women from Lublin, both locals and those who have come from different parts of the world, including Zimbabwe, Ukraine, and Belarus AHF Poland team NEWS DESK NOTE & VISUALS: Media materials and information on reproductive health will be available on-site. "The fact that Poland is located in the heart of Europe does not mean that the topic of menstruation is frequently discussed in public spaces. Both young girls and adult women still do not feel comfortable speaking openly about their experiences with menstruation. Many false beliefs and harmful myths persist, such as the inevitability of menstrual pain, which significantly affects women's daily lives," says Anna Szadkowska-Ciężka, AHF Poland's Country Program Manager. "The lack of support from healthcare professionals regarding menstruation leads to women feeling abandoned in other, more complex health matters as well. This is not a good practice!" Nearly 2 billion people menstruate globally, yet 500 million will experience period poverty—including the lack of access to menstrual health products, safe and clean facilities, and accepting communities. These barriers, along with stigma, can lead to poor health outcomes, missing school or work, and adverse effects on mental health. This Menstrual Health Day – let's fight period poverty and end the stigma. AIDS Healthcare Foundation (AHF), the largest global AIDS organization, currently provides medical care and/or services to over 2.2 million clients in 48 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Europe. To learn more about AHF, please visit our website: find us on Facebook: and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare
